Colgate-Palmolive(CL) - 2025 FY - Earnings Call Presentation
2025-09-03 13:00
Barclays Global Consumer Staples Conference September 3, 2025 © 2025 Colgate-Palmolive Company TEAM NAME September 2025 Notice for Investor Presentation Please review the following presentation in conjunction with our second quarter 2025 earnings press release, our second quarter 2025 prepared management remarks and additional information regarding our non-GAAP financial measures. Our presentation contains non- GAAP financial measures, which differ from our reported results prepared in accordance with U.S. ...
Claritev Corporation (CTEV) Earnings Call Presentation
2025-09-03 13:00
Investor Presentation Company Overview September 3, 2025 1 Disclaimer Forward-Looking Statements This presentation includes statements that express our management's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, "forward-looking statements." These forward-looking statements can generally be identified by the use of forward-looking terminology, including the terms "believes," "estimates," "ant ...
Great Elm (GEG) - 2025 Q4 - Earnings Call Presentation
2025-09-03 12:30
Financial Performance - Great Elm achieved record results in Fiscal Q4 2025, marking the best operating quarter and fiscal year in its history[6] - Fee-paying assets under management (FPAUM) grew by 5% year-over-year as of June 30, 2025[6] - Book value per share increased by 24% from the prior year, reaching $2.65[6] - Fiscal 4Q25 revenue was $5.6 million, with revenue growth over 140% excluding a prior-year BTS property sale[34] - Assets Under Management ("AUM") as of June 30, 2025, was $759 million, up 4% from June 30, 2024[40] - Fee-Paying AUM ("FPAUM") as of June 30, 2025, was $553 million, up 5% from June 30, 2024[42] Strategic Initiatives - Great Elm launched Monomoy Construction Services, LLC ("MCS") in February 2025, expanding its real estate platform[6] - A strategic partnership with Kennedy Lewis Investment Management ("KLIM") was announced in July 2025, providing up to $150 million in leverageable capital[6] - Woodstead Value Fund, L.P ("Woodstead") purchased 4 million shares of GEG at $2.25 per share for gross proceeds of $9 million in August 2025[6] - GECC sold 1.3 million shares to an affiliate of Booker Smith, or 9.9% of outstanding common stock, at $11.65 per share for gross proceeds of $15 million[6] Capital Allocation - The Board of Directors authorized an additional $5 million of stock repurchases, bringing the total stock repurchase program to $25 million[6]
Sprinklr(CXM) - 2026 Q2 - Earnings Call Presentation
2025-09-03 12:30
Financial Performance - Total RPO reached $924 million[4], with subscription revenue accounting for 78%[4] - The company achieved a net dollar expansion rate of 102%[4] - Q2 total revenue grew by 8% year-over-year[4] - LTM Q2 FY26 subscription revenue was $735.3 million, a 5% increase year-over-year[25] - LTM Q2 FY26 total revenue reached $820.8 million, reflecting a 6% year-over-year growth[25] - The company has 149 customers with over $1 million in revenue[4] Guidance - Q3 FY26 subscription revenue is projected to be between $186 million and $187 million, a 3% increase year-over-year at the midpoint[37] - Q3 FY26 total revenue is expected to be between $209 million and $210 million, a 4% increase year-over-year at the midpoint[37] - Full-year fiscal 2026 subscription revenue is guided to be between $746 million and $748 million, a 4% increase year-over-year at the midpoint[37] - Full-year fiscal 2026 total revenue is projected to be between $837 million and $839 million, a 5% increase year-over-year at the midpoint[37]
Wave Life Sciences (WVE) Earnings Call Presentation
2025-09-03 12:30
WVE-006: RNA editing for AATD Positive RestorAATion-2 clinical data update Investor presentation September 3, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing ...
Kimberly-Clark(KMB) - 2025 FY - Earnings Call Presentation
2025-09-03 12:15
Opening Remarks Barclays Global Consumer Staples Forum 2025 September 3, 2025 Forward-Looking Statements Certain matters contained in this presentation concerning the business outlook, including raw material, energy and other input costs, our plans and expectations regarding the pending International Family Care and Professional ("IFP") joint venture transaction with Suzano ("IFP Transaction"), the anticipated charges and savings from the 2024 Transformation Initiative, cash flow and uses of cash, growth in ...
Campbell Soup(CPB) - 2025 Q4 - Earnings Call Presentation
2025-09-03 12:00
Financial Performance - Q4 Fiscal Year 2025 - Net sales increased by 1% to $2321 million compared to Q4 FY24[19, 68] - Organic net sales decreased by 3% compared to Q4 FY24[19, 68] - Adjusted EBIT decreased by 2% compared to Q4 FY24, reaching $321 million[19, 68] - Adjusted EPS decreased by 2% compared to Q4 FY24, amounting to $062[19, 68] Financial Performance - Full Fiscal Year 2025 - Net sales increased by 6% to $10253 million compared to FY24[19, 71] - Organic net sales decreased by 1% compared to FY24[19, 71] - Adjusted EBIT increased by 2% compared to FY24, reaching $1487 million[19, 71] - Adjusted EPS decreased by 4% compared to FY24, amounting to $297[19, 71] Segment Performance - Meals & Beverages organic net sales decreased by 3% in Q4 FY25[35] - Snacks organic net sales decreased by 2% in Q4 FY25[51] Fiscal Year 2026 Guidance - The company expects net sales to decline by 2% to 0%[109] - Organic net sales are projected to range from -1% to +1%[109] - Adjusted EBIT is expected to decline by 13% to 9%[109] - Adjusted EPS is projected to be in the range of $240 to $255[109]
Dollar Tree(DLTR) - 2026 Q2 - Earnings Call Presentation
2025-09-03 12:00
Financial Performance - Adjusted diluted EPS from continuing operations was $0.77, including a $0.20 positive impact from tariff timing[6] - Dollar Tree segment gross margin expanded by 20 bps, but adjusted operating margin contracted by 20 bps[7] - Q2 2025 Dollar Tree GAAP operating margin was 8.0%, a decrease of 40 bps year-over-year; Non-GAAP operating margin was 8.1%, a decrease of 30 bps year-over-year[19, 20] - Dollar Tree sales per square foot reached $237 in Q2 2025[17] Sales and Comparable Store Sales - Dollar Tree comparable store sales increased by 6.5%, driven by a 3.0% increase in traffic and a 3.4% increase in average ticket[9] - Consumables comp increased by 6.7% and discretionary comp increased by 6.1%, the highest discretionary comp growth since Q4 2022[9] - Dollar Tree sales are projected to be between $19.3 billion and $19.5 billion for fiscal year 2025, with comparable sales growth of 4% to 6%[23] Real Estate and Store Operations - 106 new Dollar Tree stores were opened, bringing the total to 9,148 open stores[9] - 26 Family Dollar Combo stores were converted to full Dollar Tree stores, with the remaining 31 to be converted by year-end[9] - Approximately 400 new store openings are planned for fiscal year 2025[23] Capital Allocation and Balance Sheet - $145 million of YTD free cash flow from continuing operations and $666 million of cash and cash equivalents at quarter end[9] - 5.0 million shares were repurchased in Q2 for approximately $501 million, including excise tax, with an additional 0.6 million shares purchased for approximately $71 million after quarter end[9] - $1.0 billion of maturing May 2025 4.00% senior notes were paid off with cash on hand and commercial paper borrowings[9] - The sale of the Family Dollar business was completed for a purchase consideration of $1.0 billion, resulting in net proceeds of $800 million after adjustments[9]
Alumis (ALMS) Earnings Call Presentation
2025-09-03 12:00
Corporate Presentation September 2025 This presentation contains trademarks, service marks, trade names and copyrights of Alumis and other companies which are the property of their respective owners. This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the uses for which they are being studied. This pr ...
Macy's(M) - 2026 Q2 - Earnings Call Presentation
2025-09-03 12:00
Kenneth Cole @ Macy's 2Q25 Earnings September 3, 2025 Safe Harbor Statement All statements in this presentation that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of Macy's, Inc. management and are subject to significant risks and uncertainties. Actual results could differ materially from those expressed in or implied by the forward-looking st ...